SEK232.6 0.0 0.0%
Last Trade - 05/03/21
| Market Cap | ÂŁ2.03bn |
| Enterprise Value | ÂŁ2.79bn |
| Revenue | ÂŁ949.6m |
| Position in Universe | th / 1831 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3,389 | 4,678 | 5,332 | 6,374 | 7,457 | 11,069 | 11,972 | 12,706 | +26.7% | ||
| +14.4 | -13.9 | +43.2 | +13.8 | +35.9 | +39.1 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Recipharm publ AB is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO). It is divided in two business areas: Manufacturing Services, supplying a range of pharmaceutical products in different dosage forms, such as solid dose, semi solids, beta-lactams, hormones, dry powder metered dose inhalers, oral liquids and granulates, among others; and Development and Technology, offering clinical supply, product development, formulation, analytical development, stability studies, packaging development and raw material selection, as well as regulatory advice. It is also engaged in the development of own product portfolio. The Company targets two customer segments: large pharmaceutical companies, outsourcing part of their production; and small and medium-sized enterprises, outsourcing manufacturing and development services. Recipharm publ AB operates as a parent entity of the Recipharm Group, comprising approximately 15 subsidiaries.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Public Since | April 3, 2014 |
| No. of Shareholders: | n/a |
| No. of Employees: | 7,383 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | OMX Nordic Exchange Stockholm |
| Shares in Issue | 101,485,683 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Box 603 Drottninggatan 29, STOCKHOLM, 101 32, Sweden |
| Web | https://www.recipharm.com/ |
| Phone | +46 8 6025200 |
| Contact | () |
| Auditors | Ernst & Young AB |
As of 05/03/21, shares in Recipharm AB (publ) are trading at SEK232.6, giving the company a market capitalisation of ÂŁ2.03bn. This share price information is delayed by 15 minutes.
Shares in Recipharm AB (publ) are currently trading at SEK232.6 and the price has moved by 98.35% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Recipharm AB (publ) price has moved by 53.7% over the past year.
Of the analysts with advisory recommendations for Recipharm AB (publ), there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Recipharm AB (publ) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Recipharm AB (publ) is scheduled to issue upcoming financial results on the following dates:
Recipharm AB (publ) does not currently pay a dividend.
Recipharm AB (publ) does not currently pay a dividend.
Recipharm AB (publ) does not currently pay a dividend.
To buy shares in Recipharm AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Recipharm AB (publ) are currently trading at SEK232.6, giving the company a market capitalisation of ÂŁ2.03bn.
Here are the trading details for Recipharm AB (publ):
We were not able to load our ranking data for Recipharm AB (publ)
Shares in Recipharm AB (publ) are currently priced at SEK232.6. At that level they are trading at 1.98% premium to the analyst consensus target price of 0.00.
Analysts covering Recipharm AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of 5.943 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Recipharm AB (publ). Over the past six months, the relative strength of its shares against the market has been 36.06%. At the current price of SEK232.6, shares in Recipharm AB (publ) are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Recipharm AB (publ) PE ratio based on its reported earnings over the past 12 months is 53.2. The shares are currently trading at SEK232.6.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We were unable to find the directors for Recipharm AB (publ).
Here are the top five shareholders of Recipharm AB (publ) based on the size of their shareholding:
